New Study Reveals Paxlovid’s Limited Effectiveness in Vaccinated Older Adults

A groundbreaking UCLA-led study has challenged the perceived effectiveness of Paxlovid, an antiviral treatment, in reducing hospitalizations and mortality from COVID-19 among vaccinated older adults. The research questions whether the benefits seen in unvaccinated middle-aged individuals apply to their vaccinated older counterparts.

Key Findings of the Study

The study, to be published in the prestigious journal JAMA, found no significant reduction in COVID-19 hospitalizations and deaths among vaccinated older adults who took Paxlovid. This contrasts with Pfizer’s 2022 clinical trial, which showed reduced hospitalization in unvaccinated middle-aged adults.

“Our study effectively rules out the notion that Paxlovid causes large reductions in COVID-19 hospitalization in vaccinated older adults,” stated Dr. John Mafi, an associate professor at the David Geffen School of Medicine at UCLA. “While we cannot rule out a small reduction, Paxlovid’s potential effect among this group is four times weaker than originally reported.”

Why the Study Matters

The findings raise significant questions about the continued widespread use and high cost of Paxlovid. Pfizer’s 2022 clinical trial has long influenced the perception of Paxlovid’s effectiveness, justifying its high price tag of approximately $1,650 per treatment course and its global distribution.

“Since the strongest predictor of severe COVID-19 is advanced age, it has been crucial to obtain evidence on whether Paxlovid’s benefits generalize to this vital group,” Dr. Mafi emphasized.

The Use of a Unique Natural Experiment

To ensure accurate results, the study utilized a unique natural experiment created by age-based restrictions on Paxlovid access. This approach allowed researchers to analyze the drug’s impact without the common pitfalls of observational research, such as unobserved confounding.

“Because access to Paxlovid in this study was effectively randomized for those close to the age 70 cutoff, our results are unlikely to reflect unobserved confounding,” explained Sitaram Vangala, a biostatistician at UCLA. “This helps explain the negative findings compared to observational studies that have shown large reductions in hospitalization and mortality.”

Implications for Future Research and Policy

The study underscores the urgent need for further randomized clinical trials to investigate Paxlovid’s effects in higher-risk populations, such as older individuals who are frail or immunosuppressed.

“Our findings highlight the importance of continued research to better understand Paxlovid’s impact on those most vulnerable to severe COVID-19,” said Dr. Katherine Kahn, a distinguished professor of medicine at UCLA.

This research not only challenges current perceptions of Paxlovid’s effectiveness but also highlights the critical need for targeted and evidence-based healthcare policies in light of ongoing public health challenges.

Funding and Collaborations

The study was funded by the Commonwealth Fund and a National Institute on Aging Beeson Emerging Leaders in Aging Research Career Development Award. Additional support came from ICES, which receives annual grants from the Ontario Ministry of Health and the Ministry of Long-Term Care.

Conclusion

The UCLA-led study marks a significant shift in understanding Paxlovid’s role in COVID-19 management, particularly for vaccinated older adults. These findings urge healthcare providers, policymakers, and the broader public to reconsider and potentially reevaluate the use and cost of this antiviral treatment.

As new insights emerge, the importance of rigorous, peer-reviewed research in shaping public health strategies cannot be overstated.